Apalutamide associated with improved 2-year survival vs enzalutamide in mCSPC

[Mascouche]

At the 24-month time point, patients who received apalutamide had a 23% reduction in the risk of death compared with patients who initiated enzalutamide.

"Apalutamide (Erleada) was found to provide a significant improvement in overall survival (OS) at 24 months compared with enzalutamide (Xtandi) in the treatment of androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-sensitive prostate cancer (mCSPC), according to data from a head-to-head retrospective analysis presented at the 6th European Congress of Oncology Pharmacy in Lisbon, Portugal."

Full article here: urologytimes.com/view/apalu...

[Tinkudi]

does this mean it would be better to switch to erleada for those relatively new on xtandi

[Tall_Allen]

Other retrospective studies found that other ARSis are better. They come out with conflicting results because they are retrospective and are flawed by selection bias.